MomentumSwingPulse.com

$WLFC Willis Lease Finance announces a definitive agreement to acquire 12 commercial aircraft and 13 aircraft engines, financed and integrated into WLFC's asset management and leasing platform. The move expands WLFC's leasing portfolio and strengthens technical, asset management, and aftermarket capabilities, with potential to grow the customer base and support worldwide aviation asset lifecycle. The deal is scheduled with customary closing conditions and aligns with strategic growth timing and regulatory milestones announced on 14 July 2026, signaling upside potential from engine-based programs such as ConstantThrust.

$BUSE Busey extends Dukeman’s term, signaling leadership stability during a period of ongoing strategic execution. The move reinforces a profitability-focused, well-capitalized franchise with a broad regional footprint (80 locations across 10 states) and a sizable workforce (~1,900 associates). The extension also layers in potential upside as the bank maintains a strong core deposit franchise and positions for continued growth, with Dukeman retaining at least 300,000 shares of BUSE (FBC) for two years post-tenure, implying alignment with shareholder value. Dilution risk remains a consideration for near-term holders.

$CELC FDA approves REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA WT locally advanced or metastatic breast cancer, marking the first pan-PI3K and mTORC1/2 inhibitor cleared. The pivotal data show a 7.4-month improvement in PFS vs 2.0 months (HR 0.33; 95% CI 0.24-0.48; p<0.0001) and an ORR of 28% for the combo with fulvestrant, with median DOR of 12.0 months. The approval aligns with a late Q3 2026 commercial launch, and the HR+/HER2- cohort (~70% of breast cancers) includes ~60% PIK3CA WT, supporting sizable near-term demand despite rash safety signals observed in 40% of patients. #Biotech #FDA

$CELC FDA approval of REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA WT locally advanced or metastatic breast cancer marks the first pan-PI3K and mTORC1/2 inhibitor cleared. The pivotal data show PFS 7.4 months vs 2.0 with fulvestrant alone (HR 0.33, p<0.0001) and ORR 28% with a median DOR of 12.0 months, with roughly 60% of HR+/HER2- tumors being PIK3CA WT. A commercial launch is expected in late Q3 2026, positioning CELC to ride regulatory clearance into early commercialization. #Biotech #FDA

$CSTL Castle Biosciences (CSTL) gains a regulatory tailwind as the New York State DOH approves the AdvanceAD-Tx test, expanding clinical utility and enabling more personalized dermatology decisions. The event, announced on 14 Jul 2026 and bearing an effective timestamp around 16:30 ET, is poised to support near-term commercialization in New York and potentially broaden payer coverage. This creates a tangible upside trajectory beyond the headline approval, with positive implications for adoption and market access in a key regional market. #FDA

$MOBI Two-year Neurology data from the VNS-REHAB pivotal trial show durable upper-limb recovery with Vivistim Paired VNS, with a 76% responder rate on FMA-UE and/or WMFT and average gains of +7.5 FMA-UE and +0.63 WMFT, exceeding MCID thresholds (≥6 and ≥0.4, respectively). Follow-up included 49 participants at two years (n=108 total). Results reinforce the clinical evidence base and could support expanded post-approval adoption and real-world utilization for Vivistim therapy.

$ORIC ORIC Pharmaceuticals announced the Himalayas-1 global Phase 3 trial in metastatic castration-resistant prostate cancer evaluating rinzimetostat in combination with NUBEQA (darolutamide), backed by a clinical collaboration with Bayer and no-cost NUBEQA supply. The move advances rinzimetostat into a pivotal study while ORIC retains full global development and commercial rights, preserving upside irrespective of Bayer participation. Key anchors: Phase 3 in mCRPC and no-cost NUBEQA support, with execution anticipated to drive near-term clinical milestones. #Biotech

$BIIB Biogen's Phase 2 CELIA data on diranersen were presented at AAIC, highlighting robust biomarker signals despite missing the primary endpoint. Diranersen achieved CSF total tau reductions of 50–65% from baseline across all doses, with Tau PET decreases observed across all evaluated brain regions in the n=131 substudy. While the primary endpoint was not met, the combination of strong target engagement and widespread tau signal attenuation at AAIC suggests meaningful upside interest around biomarker-driven narratives and potential follow-on exploration in later-stage development. #Biotech

$QTEX QTEX announces a commercial order from a government-owned customer and has begun production, signaling a direct-to-supply path for custom AME components. The order validation followed extensive testing of dielectric performance, with high repeatability identified as a key factor. The setup identifies immediate delivery within days and a follow-on program that suggests potential upsell and scale across broader deployment and additional quantities, all powered by QTEX’s proprietary AME technology and customized specifications.

$VERI Veritone announced an exclusive global content licensing agreement with the Pac-12 Conference on a multi-year term, expanding its licensing footprint with a key collegiate content partner. The deal centers on an exclusive distribution framework across Veritone’s platforms, with potential for recurring licensing revenue tied to Pac-12 content across multiple years. The publicized move reinforces Veritone’s content-licensing cadence in 2026 and signals a steady, contract-driven revenue stream anchored by a high-visibility partner.

$AIP Arteris (AIP) announces a July 14, 2026 expansion of its partnership with Arm to boost security assurance across Arm CPU IP. The tie-in integrates Cycuity Radix security methodology into the Arm CPU design flow, reinforcing security from architecture onward. With five years of prior collaboration underpinning the move, the expanded collaboration leverages Arteris NoC interconnect IP, SoC software, and hardware security to improve security and efficiency across Arm-based processors, signaling a material, multi-element catalyst in the post-close window. #Semiconductors

$ERNA Ernexa Therapeutics advances toward an IND in Q3 2026 for ERNA-101, with a first-in-human Phase 1 start anticipated in Q4 2026. The program leverages a differentiated ERNA-101 platform and an off-the-shelf iMSC manufacturing approach, aiming to transform immunologically 'cold' tumors such as ovarian cancer. The timing aligns regulatory progress with robust preclinical data, signaling a tangible near-term catalyst as IND readiness and early human dosing become facilitators of upside momentum. #Biotech

$GMEX GMEX Robotics Corporation signed a non-binding Letter of Intent to acquire an AI platform to build social world models for human-centric mass deployment. The announcement, dated July 14, 2026 at 08:30 ET, highlights a strategic objective to expand GMEX's AI-powered automation. Key caveats include that the LOI is non-binding and contingent on due diligence, definitive agreements, regulatory and third-party approvals, and closing conditions; discussions could terminate at any time and there is no guarantee the transaction proceeds on current terms or at all. #AI

$SBEV Splash Beverage Group reports a major balance sheet reset with legacy liabilities negotiated down from about $3.3 million to roughly $550,000, and an anticipated $2.75 million gain from extinguishment of indebtedness. The board approved a reverse stock split to meet NYSE American minimum. Coupled with strategic moves including a Avicanna investment and CannEpil licensing, the company signals a deliberate transformation toward a cannabinoid health platform, driving upside balance-sheet momentum into the next session.

$LHAI OpenLink AI Compute Platform launches with Linkhome Holdings signing a definitive two-year enterprise AI compute services agreement, signaling near-term commercial rollout. The contract value is up to US$10.5 million over 24 months, with OpenLink being the first enterprise customer and the initial commercial deployment. The arrangement covers GPU computing resources, AI cloud infrastructure, network connectivity, orchestration software, and technical support, highlighting a tangible revenue recognition pathway. #AI #Semiconductors

$LBRT On July 14, 2026, SLB and Liberty Energy announced a strategic alliance focused on data center infrastructure and power, tying the collaboration to a joint push into energy-intense data operations. The tie-up signals a concrete, non-earnings business collaboration intended to accelerate deployment of shared infrastructure capabilities and related services, with the announcement date cited as the driver for timing. The arrangement represents a material, cross-industry partnership rather than an isolated project, potentially impacting the firms’ near-term data-center-capability profile in the marketplace. #Earnings #AI

$CRMT America's Car-Mart (CRMT) reports Q4 FY2026 and full-year results showing meaningful profitability and liquidity strain. Q4 retail units sold were 11,411, down 27.1% year over year. Interest expense for the quarter rose to $20.0 million (+$2.6 million, +15.1%), reflecting the October 2025 $300 million term loan and December 2025 asset-backed securitization. The company cites tight liquidity with going-concern considerations; for the year ended April 30, 2026, net loss was $(139.111) million and provision for credit losses reached $419.230 million, while operating cash flow totaled $64.959 million. Balance sheet metrics show an allowance for credit losses at 25.15% of net principal balances. #Earnings

$SUPN SUPN marks the five-year FDA approval anniversary for Qelbree (viloxazine extended-release) in ADHD, underscoring ongoing real-world adoption for both pediatric (6-17) and adult populations. The program features a non-stimulant profile with a multimodal mechanism, reinforced by a January 2025 lactation labeling update. With roughly 16 million US adults and 7 million children/teens living with ADHD, the anniversary narrative reinforces Qelbree’s FDA-validated positioning across age groups. #Biotech #FDA

$CRDL CardiolRx received FDA Orphan Drug Designation for recurrent pericarditis, aligning with ongoing MAVERIC Phase III pivotal trial (NCT06708299) after a completed MAVERIC-Pilot (NCT05494788). ARCHER Phase II in acute myocarditis has also completed (NCT05180240), while CRD-38 advances as a novel subcutaneous formulation for inflammatory heart disease amid US healthcare costs above $30 billion. Together, these milestones underpin a constructive upside trajectory as regulatory recognition compounds with late-stage trial progression through 2026. #Biotech #FDA

$A FDA approval expands the PD-L1 IHC 28-8 pharmDx indication to Esophageal Squamous Cell Carcinoma, Gastric/GEJ, and Esophageal Adenocarcinoma, unlocking an expanded addressable oncology diagnostics market and strengthening the product portfolio. The regulatory milestone signals increased adoption potential across ESCC, GEJ, and esophageal cancer patients, with the 28-8 assay serving as a clinically relevant companion diagnostic and potential near-term revenue impact. #Biotech #FDA